Ottiliavej 9 DK-2500 Valby København Tel +45 36 30 13 11 Fax +45 36 43 82 62

E-mail investor@lundbeck.com www.lundbeck.com



Release No 269

15 May 2007

Share capital increase as a result of employees exercising warrants

H. Lundbeck A/S will on 16 May 2007 file an increase of its share capital by DKK 406,475 nominal value, with the Danish Commerce and Companies Agency as a result of employees exercising warrants. The registered share capital will subsequently amount to DKK 1,063,626,615 divided into 212,725,323 shares of DKK 5 each. The subscription price was DKK 108.11 per share. The new shares shall carry a right to dividend for the financial year 2007 from the time of registration of the capital increase, provided that it is decided on the annual general meeting of the company to pay a dividend for that financial year.

On 9 December 2003 (see release no. 118), the Supervisory Board of H. Lundbeck A/S resolved to grant warrants to members of the Executive Management and key employees of the company and its non-US subsidiaries. In that connection, the company granted 2,554,092 warrants.

The employees can exercise the warrants in a number of exercise periods until 30 August 2007. The latest exercise period commenced on 10 May 2007 and closes on 22 May 2007. In respect of the latest exercise period, two capital increases will be filed, the first of which will be made 16 May 2007. The second filing will be made after the latest exercise period has expired.

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

Lundbeck contacts

Investors: Media:

Jacob Tolstrup Caroline Broge
Investor Relations Manager,
North America H45 36 43 26 38

+1 201 350 0187

Ottiliavej 9 DK-2500 Valby København Tel +45 36 30 13 11 Fax +45 36 43 82 62 E-mail investor@lundbeck.com www.lundbeck.com



Stock Exchange Release No 269 - 15 May 2007

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com